Infection of defective human T-lymphotropic virus type 1. 2017

Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
Department of Rheumatology, Infectious Diseases and Laboratory Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.

In a previous study, we reported that an identical defective provirus had integrated into multiple sites of the genome of a representative human T-lymphotropic virus type 1 (HTLV-1) cell line, MT-2. A possible explanation for this may be the repeated infection of this defective provirus to a cell. Therefore, we attempted to determine whether a defective provirus could transmit during the co-culture of HTLV-1 uninfected human T-cell line, Jurkat, with MT-2 cells treated with mitomycin C. As a result, we established not only a cell line with the integration of one complete provirus, but also a cell line with the integration of one defective provirus. The rearrangement of the T-cell receptor -γ gene of these cell lines showed them to be derived from Jurkat cells. Both HTLV-1 Tax/Rex and HBZ RNA were detected in the cell line, which harbors a complete provirus. On the other hand, HBZ RNA and transcriptional product specific for the defective provirus were detected in the cell line, which harbors a defective HTLV-1 provirus only. These results suggested that a defective HTLV-1 provirus with large depletion of internal sequence could transmit to other cells. Moreover, the defective provirus can be transcriptionally active. This suggested the possibility that the defective HTLV-1 provirus found in the lymphocytes of HTLV-1 carriers and patients with adult T-cell leukemia may transmit to other T-cells in vivo. The results also suggested that defective provirus in HTLV-1 carriers could be functional and may play a role in leukemogenesis.

UI MeSH Term Description Entries
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D015329 Gene Rearrangement, T-Lymphocyte Ordered rearrangement of T-cell variable gene regions coding for the antigen receptors. Gene Rearrangement, T-Cell Antigen Receptor,T-Cell Gene Rearrangement,T-Lymphocyte Gene Rearrangement,Gene Rearrangement, T-Cell,Gene Rearrangement, T Cell,Gene Rearrangement, T Cell Antigen Receptor,Gene Rearrangement, T Lymphocyte,Gene Rearrangements, T-Cell,Gene Rearrangements, T-Lymphocyte,Rearrangement, T-Cell Gene,Rearrangement, T-Lymphocyte Gene,Rearrangements, T-Cell Gene,Rearrangements, T-Lymphocyte Gene,T Cell Gene Rearrangement,T Lymphocyte Gene Rearrangement,T-Cell Gene Rearrangements,T-Lymphocyte Gene Rearrangements
D015368 Human T-lymphotropic virus 1 A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC). ATLV,Adult T-Cell Leukemia-Lymphoma Virus I,HTLV-1,HTLV-I,Human T-Cell Leukemia Virus I,Leukemia Virus I, Human T-Cell,T-Cell Leukemia Virus I, Human,Adult T Cell Leukemia Lymphoma Virus I,Human T Cell Leukemia Virus I,Leukemia Lymphoma Virus I, Adult T Cell,Leukemia Virus I, Human T Cell,T Cell Leukemia Virus I, Human,Human T lymphotropic virus 1
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D016662 Virus Integration Insertion of viral DNA into host-cell DNA. This includes integration of phage DNA into bacterial DNA; (LYSOGENY); to form a PROPHAGE or integration of retroviral DNA into cellular DNA to form a PROVIRUS. Integration, Provirus,Integration, Virus,Provirus Integration,Viral integration,Integrations, Provirus,Integrations, Virus,Provirus Integrations,Viral integrations,Virus Integrations,integration, Viral,integrations, Viral
D016692 Receptors, Antigen, T-Cell, gamma-delta T-cell receptors composed of CD3-associated gamma and delta polypeptide chains and expressed primarily in CD4-/CD8- T-cells. The receptors appear to be preferentially located in epithelial sites and probably play a role in the recognition of bacterial antigens. The T-cell receptor gamma/delta chains are separate and not related to the gamma and delta chains which are subunits of CD3 (see ANTIGENS, CD3). Antigen Receptors, T-Cell, gamma-delta,T-Cell Receptors delta-Chain,T-Cell Receptors gamma-Chain,T-Cell Receptors, gamma-delta,TcR gamma-delta,Antigen T Cell Receptor, delta Chain,Antigen T Cell Receptor, gamma Chain,Receptors, Antigen, T Cell, gamma delta,T Cell Receptors, gamma delta,T-Cell Receptor delta-Chain,T-Cell Receptor gamma-Chain,T-Cell Receptor, gamma-delta,T Cell Receptor delta Chain,T Cell Receptor gamma Chain,T Cell Receptor, gamma delta,T Cell Receptors delta Chain,T Cell Receptors gamma Chain,TcR gamma delta,delta-Chain, T-Cell Receptor,delta-Chain, T-Cell Receptors,gamma-Chain, T-Cell Receptor,gamma-Chain, T-Cell Receptors,gamma-delta T-Cell Receptor,gamma-delta T-Cell Receptors,gamma-delta, TcR
D019169 Jurkat Cells A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation. Cell, Jurkat,Cells, Jurkat,Jurkat Cell

Related Publications

Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
June 2000, Bailliere's best practice & research. Clinical haematology,
Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
March 2011, International journal of cancer,
Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
May 1996, The Australasian journal of dermatology,
Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
May 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
June 1999, Lancet (London, England),
Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
September 2005, Rinsho byori. The Japanese journal of clinical pathology,
Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
December 2003, Current opinion in ophthalmology,
Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
November 2001, The Journal of infectious diseases,
Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
February 1994, The British journal of ophthalmology,
Yuuki Hashikura, and Kazumi Umeki, and Kunihiko Umekita, and Hajime Nomura, and Akiteru Yamada, and Ikuo Yamamoto, and Hiroo Hasegawa, and Katsunori Yanagihara, and Akihiko Okayama
April 2009, Infectious disorders drug targets,
Copied contents to your clipboard!